GEN News Highlights

Sequenom and its subsidiaries will purchase Illumina'sHiSeq 2000 platform and consumables for use in developing a noninvasive prenatal test designed to detect an overabundance of chromosome 21 in pregnant women, a result associated with fetal Down syndrome.

Under their three-year supply agreement, Sequenom and Illumina said they will work collaboratively toward a submission for regulatory approval of an in vitro sequencing-based diagnostic product for detecting fetal chromosomal abnormalities.

"This agreement is an important step in bringing our proprietary trisomy test to market, giving us the scalability, speed to market, and supply chain necessary to address the commercial opportunity of our noninvasive prenatal test for trisomy 21," states Sequenom chairman and CEO Harry F. Hixson Jr., Ph.D.

Last month Dr. Hixson said at a healthcare conference that Sequenom plans to submit a PMA application to the FDA for its SensiGene® Trisomy 21 (T21) test by the end of 2012. Sequenom representatives began talks with the FDA in January about the preclinical and clinical studies it would need to gain premarket approval.

Also in June Sequenom said it secured a $30 million credit facility—a $20 million term loan plus a $10 million revolving line of credit—to support the development and commercialization of new laboratory developed tests (LDTs).

Sequenom announced in May that its molecular diagnostics reference laboratory, the wholly owned subsidiary Sequenom Center for Molecular Medicine, completed testing samples from the pivotal Sequenom-funded Women and Infants clinical validation study to evaluate the clinical performance of its LDT. Study results are expected to be announced later this year following their submission and publication in a yet-to-be determined peer-reviewed journal.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.